Ablynx [ABLX] today announced that it has earned a €5 million milestone payment following Boehringer Ingelheim's decision to initiate development with its lead Nanobody candidate that was selected in May 2010.
In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target.
The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales.
"We are delighted that Boehringer Ingelheim is making further progress with the Nanobody lead candidate which has the potential to be a first-in-class therapy for Alzheimer's disease and we look forward to this product advancing into the clinic in 2012." said Dr. Edwin Moses, Chairman and CEO of Ablynx. "This programme illustrates the wide applicability and advantages of our Nanobody platform in addressing diseases as complex as Alzheimer's." He added.:
This is the second milestone payment that Ablynx receives as part of our Alzheimer's research collaboration with Boehringer Ingelheim,
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
